C4 Therapeutics (CCCC) FCF Margin (2019 - 2026)

C4 Therapeutics' FCF Margin history runs 8 years deep, the most recent figure standing at 487.35% for Q1 2026.

• In Q1 2026, FCF Margin fell 2749.0% year-over-year to 487.35%; the TTM figure through Mar 2026 stood at 275.37% (down 7302.0% YoY), while the FY2025 annual figure was 276.24%, down 9263.0% from the prior year.
• FCF Margin for Q1 2026 stood at 487.35%, down from 206.31% in the prior quarter.
• The five-year high for FCF Margin was 41.54% in Q2 2024, with the low at 1072.81% in Q4 2022.
• The 5-year median for FCF Margin is 349.73% (2022), against an average of 438.8%.
• The sharpest annual moves came in 2022 and 2024: FCF Margin plunged 94495 bps in 2022, then surged 68515 bps in 2024.
• C4 Therapeutics' FCF Margin stood at 1072.81% in 2022, then jumped by 31 bps to 741.06% in 2023, then soared by 53 bps to 346.3% in 2024, then soared by 40 bps to 206.31% in 2025, then tumbled by 136 bps to 487.35% in 2026.
• Business Quant data shows CCCC's FCF Margin at 487.35% in Q1 2026, 206.31% in Q4 2025, and 276.46% in Q3 2025.